Eli Lilly

LLY

Market cap $1.02T

In the latest trading session, Eli Lilly (LLY) closed at $1, marking a -2.73% move from the previous day.

Lilly stock has soared in the double-digits over the past couple of months. A potential stock split could bring the stock price down to more accessible levels.

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Thursday's announcement that Eli Lilly will acquire AtaiBeckley, a clinical-stage maker of psychedelic drugs, for up to $3.8 billion indicates Big Pharma's increasing embrace of a long-stigmatized class of medications as alternatives for treating an array of mental health conditions. Several psychedelic substances — LSD, psilocybin (aka magic mushrooms), MDMA, ayahuasca and ibogaine  — are being studied by new drug companies to treat depression, post traumatic stress disorder, anxiety, eating disorders and alcohol and drug addiction.

The three biggest US pharma names by market cap trade at very different setups right now: Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) at $247.02 screens as the most compelling on fundamentals, Eli Lilly (NYSE:LLY) at $1,156.63 looks fully valued, and AbbVie (NYSE:ABBV) at $244.11 appears stretched relative to its growth outlook.

The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rate both quantitatively and qualitatively and select the top 10 names from an initial list of nearly 500 dividend stocks. The final list of ten stocks is chosen based on sector diversity, high-growth quality scores, and positive momentum and is suitable for investors in the accumulation phase.

MichaelAaron Flicker examines the growing impact of GLP-1 medications on consumer behavior, noting that roughly one in five American households has someone using a GLP-1 drug. He explains how that trend is reshaping spending habits and discusses the implications for restaurants as well as food and beverage stocks.

Viking Therapeutics just launched its next-gen weight loss program. Novo Nordisk and Eli Lilly are already deep into the development process with comparable programs.

I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics, and inflation while generating attractive income. My "ALLKA Dividend Rating" model separates quality dividend opportunities from yield traps by analyzing dividend sustainability, growth prospects, and valuation. The article explores three dividend strategies, "High-Yield Defensive," "Balanced Income," and "Pure Growth," designed for goals ranging from high yield to dividend growth.

Eli Lilly's growth is being driven by its GLP-1 drugs right now.  Mounjaro and Zepbound accounted for nearly two-thirds of the drug maker's first-quarter 2026 revenues.